Identification of vaccine antigens using integrated proteomic analyses of surface immunogens from serogroup B Neisseria meningitidis

Journal of Proteomics

Volumn 101, Issue , 2014, Pages 63-76

  Tsolakos, Nikos ^a,b,d   Brookes, Charlotte ^c   Taylor, Stephen ^c   Gorringe, Andrew ^c   Tang, Christoph M ^b,e   Feavers, Ian M ^a   Wheeler, Jun X ^a  

^a NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^b IMPERIAL COLLEGE LONDON   (United Kingdom)

^c PUBLIC HEALTH ENGLAND   (United Kingdom)

^d BABRAHAM INSTITUTE   (United Kingdom)

^e UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Differential gel electrophoresis; Immunoproteome; Macrophage infectivity potentiator; Meningococcal vaccines; Neisseria meningitidis; Proteomics

Indexed keywords

ABC TRANSPORTER; ANTISERUM; COMPLEMENT COMPONENT C3C; COMPLEMENT FACTOR H; COMPLEMENT MEMBRANE ATTACK COMPLEX; LIPOPROTEIN; MEMBRANE ANTIGEN; MEMBRANE PROTEIN; MENINGOCOCCUS VACCINE; OUTER MEMBRANE PROTEIN; PROTEINASE K; BACTERIAL ANTIGEN; BACTERIAL PROTEIN;

ADULT; AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN DETECTION; ARTICLE; BACTERIUM ISOLATE; CELL MEMBRANE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOBLOTTING; IMMUNOGENICITY; MACROPHAGE; MOUSE; NEISSERIA MENINGITIDIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; EPIDEMIC MENINGITIS; IMMUNOLOGY; ISOLATION AND PURIFICATION; METABOLISM; PROCEDURES;

ANIMALS; ANTIGENS, BACTERIAL; ANTIGENS, SURFACE; BACTERIAL PROTEINS; ENDOPEPTIDASE K; FEMALE; MENINGITIS, MENINGOCOCCAL; MENINGOCOCCAL VACCINES; MICE; MICE, INBRED BALB C; NEISSERIA MENINGITIDIS, SEROGROUP B; PROTEOMICS;

EID: 84896865605     PISSN: 18743919     EISSN: 18767737     Source Type: Journal    
DOI: 10.1016/j.jprot.2014.02.013     Document Type: Article

References (65)

1. Vedros N.A. Development of meningococcal serogroups. Evolution of meningococcal disease 1987, 33-37. CRC Press Inc., Boca Raton, FL. N.A. Vedros (Ed.).
2. Sadarangani M., Pollard A.J. Serogroup B meningococcal vaccines-an unfinished story. Lancet Infect Dis 2010, 10:112-124.
3. Devi S.J., Zollinger W.D., Snoy P.J., Tai J.Y., Costantini P., Norelli F., et al. Preclinical evaluation of group B Neisseria meningitidis and Escherichia coli K92 capsular polysaccharide-protein conjugate vaccines in juvenile rhesus monkeys. Infect Immun 1997, 65:1045-1052.
4. Finne J., Bitter-Suermann D., Goridis C., Finne U. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J Immunol 1987, 138:4402-4407.
5. Bai X., Borrow R. Genetic shifts of Neisseria meningitidis serogroup B antigens and the quest for a broadly cross-protective vaccine. Expert Rev Vaccines 2010, 9:1203-1217.
6. Feavers I.M., Pizza M. Meningococcal protein antigens and vaccines. Vaccine 2009, 27S:B42-B50.
7. Giuliani M.M., Adu-Bobie J., Comanducci M., Aricò B., Savino S., Santini L., et al. A universal vaccine for serogroup B meningococcus. Proc Natl Acad Sci U S A 2006, 103:10834-10839.
8. van den Dobbelsteen G.P., van Dijken H.H., Pillai S., van Alphen L. Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine 2007, 25:2491-2496.
9. Cordwell S.J. Technologies for bacterial surface proteomics. Curr Opin Microbiol 2006, 9:320-329.
10. Doro F., Liberatori S., Rodríguez-Ortega M.J., Rinaudo C.D., Rosini R., Mora M., et al. Surfome analysis as a fast track to vaccine discovery: identification of a novel protective antigen for Group B Streptococcus hypervirulent strain COH1. Mol Cell Proteomics 2009, 8:1728-1737.
11. Dreisbach A., Hempel K., Buist G., Hecker M., Becher D., van Dijl J.M. Profiling the surfacome of Staphylococcus aureus. Proteomics 2010, 10:3082-3096.
12. Insenser M.R., Hernáez M.L., Nombela C., Molina M., Molero G., Gil C. Gel and gel-free proteomics to identify Saccharomyces cerevisiae cell surface proteins. J Proteomics 2010, 73:1183-1195.
13. Mandanici F., Gómez-Gascón L., Garibaldi M., Olaya-Abril A., Luque I., Tarradas C., et al. A surface protein of Streptococcus suis serotype 2 identified by proteomics protects mice against infection. J Proteomics 2010, 73:2365-2369.
14. Rodríguez-Ortega M.J., Norais N., Bensi G., Liberatori S., Capo S., Mora M., et al. Characterization and identification of vaccine candidate proteins through analysis of the group A Streptococcus surface proteome. Nat Biotechnol 2006, 24:191-197.
15. Severin A., Nickbarg E., Wooters J., Quazi S.A., Matsuka Y.V., Murphy E., et al. Proteomic analysis and identification of Streptococcus pyogenes surface-associated proteins. J Bacteriol 2007, 189:1514-1522.
16. Tjalsma H., Lambooy L., Hermans P.W., Swinkels D.W. Shedding & shaving: disclosure of proteomic expressions on a bacterial face. Proteomics 2008, 8:1415-1428.
17. Walters M.S., Mobley H.L. Identification of uropathogenic Escherichia coli surface proteins by shotgun proteomics. J Microbiol Methods 2009, 78:131-135.
18. Sabarth N., Hurvitz R., Schmidt M., Zimny-Arndt U., Jungblut P.R., Meyer T.F., et al. Identification of Helicobacter pylori surface proteins by selective proteinase K digestion and antibody phage display. J Microbiol Methods 2005, 62:345-349.
19. Mendum T.A., Newcombe J., McNeilly C.L., McFadden J. Towards the immunoproteome of Neisseria meningitidis. PLoS One 2009, 4:e5940.
20. Williams J.N., Skipp P.J., O'Connor C.D., Christodoulides M., Heckels J.E. Immunoproteomic analysis of the development of natural immunity in subjects colonized by Neisseria meningitidis reveals potential vaccine candidates. Infect Immun 2009, 77:5080-5089.
21. Exley R.M., Shaw J., Mowe E., Sun Y.H., West N.P., Williamson M., et al. Available carbon source influences the resistance of Neisseria meningitidis against complement. J Exp Med 2005, 201:1637-1645.
22. Findlow J., Taylor S., Aase A., Horton R., Heyderman R., Southern J., et al. Comparison and correlation of Neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac. Infect Immun 2006, 74:4557-4565.
23. Fredriksen J.H., Rosenqvist E., Wedege E., Bryn K., Bjune G., Froholm L.O., et al. Production, characterization and control of MenB-vaccine "Folkehelsa": an outer membrane vesicle vaccine against group B meningococcal disease. NIPH Ann 1991, 14:67-79.
24. Bradford M.M. A rapid and sensitive for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976, 72:248-254.
25. Tsolakos N., Techanukul T., Wallington A., Zhao Y., Jones C., Nagy J., et al. Comparison of two combinations of cyanine dyes for prelabelling and gel electrophoresis. Proteomics 2009, 9:1727-1730.
26. Yan J.X., Devenish A.T., Wait R., Stone T., Lewis S., Fowler S. Fluorescence two-dimensional difference gel electrophoresis and mass spectrometry based proteomic analysis of Escherichia coli. Proteomics 2002, 2:1682-1698.
27. Laemmli U.K. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227:680-685.
28. Donoghue P.M., McManus C.A., O'Donoghue N.M., Pennington S.R., Dunn M.J. CyDye immunoblotting for proteomics: co-detection of specific immunoreactive and total protein profiles. Proteomics 2006, 6:6400-6404.
29. Vipond C., Suker J., Jones C., Tang C., Feavers I.M., Wheeler J.X. Proteomic analysis of a meningococcal outer membrane vesicle vaccine prepared from the group B strain NZ98/254. Proteomics 2006, 6:3400-3413.
30. Li Y., Zhang Q., Winterbotham M., Mowe E., Gorringe A., Tang C.M. Immunization with live Neisseria lactamica protects mice against meningococcal challenge and can elicit serum bactericidal antibodies. Infect Immun 2006, 74:6348-6355.
31. Pajon R., Yero D., Niebla O., Climent Y., Sardiñas G., García D., et al. Identification of new meningococcal serogroup B surface antigens through a systematic analysis of neisserial genomes. Vaccine 2009, 28:532-541.
32. Yu N.Y., Wagner J.R., Laird M.R., Melli G., Rey S., Lo R., et al. PSORTb 3.0: improved protein subcellular localization prediction with refined localization subcategories and predictive capabilities for all prokaryotes. Bioinformatics 2010, 26:1608-1615.
33. Juncker A.S., Willenbrock H., Von Heijne G., Brunak S., Nielsen H., Krogh A. Prediction of lipoprotein signal peptides in Gram-negative bacteria. Protein Sci 2003, 12:1652-1662.
34. Hung M.C., Salim O., Williams J.N., Heckels J.E., Christodoulides M. The Neisseria meningitidis macrophage infectivity potentiator (MIP) protein induces cross-strain serum bactericidal activity and is a potential serogroup B vaccine candidate. Infect Immun 2011, 79:3784-3791.
35. Ferrari G., Garaguso I., Adu-Bobie J., Doro F., Taddei A.R., Biolchi A., et al. Outer membrane vesicles from group B Neisseria meningitidis δgna33 mutant: proteomic and immunological comparison with detergent-derived outer membrane vesicles. Proteomics 2006, 6:1856-1866.
36. Tsolakos N., Lie K., Bolstad K., Maslen S., Kristiansen P.A., Høiby E.A., et al. Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media. Vaccine 2010, 28:3211-3218.
37. Uli L., Castellanos-Serra L., Betancourt L., Dominguez F., Barbera R., Sotolongo F., et al. Outer membrane vesicles of the VA-MENGOC-BC(R) vaccine against serogroup B of Neisseria meningitidis: analysis of protein components by two-dimensional gel electrophoresis and mass spectrometry. Proteomics 2006, 6:3389-3399.
38. Vaughan T.E., Skipp P.J., O'Connor C.D., Hudson M.J., Vipond R., Elmore M.J., et al. Proteomic analysis of Neisseria lactamica and Neisseria meningitidis outer membrane vesicle vaccine antigens. Vaccine 2006, 24:5277-5293.
39. Rosenqvist E., Høiby E.A., Wedege E., Bryn K., Kolberg J., Klem A., et al. Human antibody responses to meningococcal outer membrane antigens after three doses of the Norwegian group B meningococcal vaccine. Infect Immun 1995, 63:4642-4652.
40. Wedege E., Bolstad K., Aase A., Herstad T.K., McCallum L., Rosenqvist E., et al. Functional and specific antibody responses in adult volunteers in New Zealand who were given one of two different meningococcal serogroup B outer membrane vesicle vaccines. Clin Vaccine Immunol 2007, 14:830-838.
41. Cantini F., Veggi D., Dragonetti S., Savino S., Scarselli M., Romagnoli G., et al. Solution structure of the factor H-binding protein, a survival factor and protective antigen of Neisseria meningitidis. J Biol Chem 2009, 284:9022-9026.
42. Schneider M.C., Exley R.M., Chan H., Feavers I., Kang Y.H., Sim R.B., et al. Functional significance of factor H binding to Neisseria meningitidis. J Immunol 2006, 176:7566-7575.
43. Marshall H.S., Richmond P.C., Nissen M.D., Wouters A., Baber J., Jiang Q., et al. A phase 2 open-label safety and immunogenicity study of a meningococcal B bivalent rLP2086 vaccine in healthy adults. Vaccine 2013, 31:1569-1575.
44. Keiser P.B., Biggs-Cicatelli S., Moran E.E., Schmiel D.H., Pinto V.B., Burden R.E., et al. A phase 1 study of a meningococcal native outer membrane vesicle vaccine made from a group B strain with deleted lpxL1 and synX, over-expressed factor H binding protein, two PorAs and stabilized OpcA expression. Vaccine 2011, 29:1413-1420.
45. Toneatto D., Ismaili S., Ypma E., Vienken K., Oster P., Dull P. The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans. Hum Vaccin 2011, 7:646-653.
46. Sardiñas G., Yero D., Climent Y., Caballero E., Cobas K., Niebla O. Neisseria meningitidis antigen NMB0088: sequence variability, protein topology and vaccine potential. J Med Microbiol 2009, 58:196-208.
47. Pizza M., Scarlato V., Masignani V., Giuliani M.M., Aricò B., Comanducci M., et al. Identification of vaccine candidates against serogroup B meningococcus by whole-genome sequencing. Science 2000, 287:1816-1820.
48. Hsu C.A., Lin W.R., Li J.C., Liu Y.L., Tseng Y.T., Chang C.M., et al. Immunoproteomic identification of the hypothetical protein NMB1468 as a novel lipoprotein ubiquitous in Neisseria meningitidis with vaccine potential. Proteomics 2008, 8:2115-2125.
49. Black J.R., Black W.J., Cannon J.G. Neisserial antigen H.8 is immunogenic in patients with disseminated gonococcal and meningococcal infections. J Infect Dis 1985, 151:650-657.
50. Poolman J.T., Hopman C.T.P., Zanen H.C. Immunogenicity of meningococcal antigens as detected in patient sera. Infect Immun 1983, 40:398-406.
51. Stephens D.S., Whitney A.M., Rothbard J., Schoolnik G.K. Pili of Neisseria meningitidis. Analysis of structure and investigation of structural and antigenic relationships to gonococcal pili. J Exp Med 1985, 161:1539-1553.
52. Cannon J.G., Black W.J., Nachamkin I., Stewart P.W. Monoclonal antibody that recognizes an outer membrane antigen common to the pathogenic Neisseria species but not to most nonpathogenic Neisseria species. Infect Immun 1984, 43:994-999.
53. Ray T.D., Lewis L.A., Gulati S., Rice P.A., Ram S. Novel blocking human IgG directed against the pentapeptide repeat motifs of Neisseria meningitidis Lip/H.8 and Laz lipoproteins. J Immunol 2011, 186:4881-4894.
54. Grifantini R., Bartolini E., Muzzi A., Draghi M., Frigimelica E., Berger J., et al. Previously unrecognized vaccine candidates against group B meningococcus identified by DNA microarrays. Nat Biotechnol 2002, 20:914-921.
55. Tinsley C.R., Voulhoux R., Beretti J.L., Tommassen J., Nassif X. Three homologues, including two membrane-bound proteins, of the disulfide oxidoreductase DsbA in Neisseria meningitidis: effects on bacterial growth and biogenesis of functional type IV pili. J Biol Chem 2004, 279:27078-27087.
56. Balasingham S.V., Collins R.F., Assalkhou R., Homberset H., Frye S.A., Derrick J.P., et al. Interactions between the lipoprotein PilP and the secretin PilQ in Neisseria meningitidis. J Bacteriol 2007, 189:5716-5727.
57. Galat A., Metcalfe S.M. Peptidylproline cis/trans isomerases. Prog Biophys Mol Biol 1995, 63:67-118.
58. Cianciotto N.P., Fields B.S. Legionella pneumophila mip gene potentiates intracellular infection of protozoa and human macrophages. Proc Natl Acad Sci U S A 1992, 89:5188-5191.
59. Echenique-Rivera H., Muzzi A., Del Tordello E., Seib K.L., Francois P., Rappuoli R., et al. Transcriptome analysis of Neisseria meningitidis in human whole blood and mutagenesis studies identify virulence factors involved in blood survival. PLoS Pathog 2011, 7:e1002027.
60. Christodoulides M., Brooks J.L., Rattue E., Heckels J.E. Immunization with recombinant class 1 outer-membrane protein from Neisseria meningitidis: influence of liposomes and adjuvants on antibody avidity, recognition of native protein and the induction of a bactericidal immune response against meningococci. Microbiology 1998, 144:3027-3037.
61. Hung M.C., Heckels J.E., Christodoulides M. The Adhesin Complex Protein (ACP) of Neisseria meningitidis is a new adhesin with vaccine potential. MBio 2013, 4:e00041-13.
62. Granoff D.M. Relative importance of complement-mediated bactericidal and opsonic activity for protection against meningococcal disease. Vaccine 2009, 27S:B117-B125.
63. Plested J.S., Granoff D.M. Vaccine-induced opsonophagocytic immunity to Neisseria meningitidis group B. Clin Vaccine Immunol 2008, 15:799-804.
64. Arenas J., Abel A., Sánchez S., Marzoa J., Berrón S., van der Ley P., et al. A cross-reactive neisserial antigen encoded by the NMB0035 locus shows high sequence conservation but variable surface accessibility. J Med Microbiol 2008, 57:80-87.
65. Moe G.R., Tan S., Granoff D.M. Differences in surface expression of NspA among Neisseria meningitidis group B strains. Infect Immun 1999, 67:5664-5675.